ClinicalTrials.Veeva

Menu

13C-Pyruvate Breath Test (PBT)

University of Florida logo

University of Florida

Status and phase

Completed
Phase 1

Conditions

Healthy

Treatments

Drug: 13C-Pyruvate 13C-lactate and dichloroacetate

Study type

Interventional

Funder types

Other

Identifiers

NCT01807702
IRB# 654-10

Details and patient eligibility

About

The purpose of the test is to measure an enzyme called pyruvate. Subjects will fast for 12 hours and then undergo a breath test, have blood drawn, and cells from the inside of the mouth collected over a 12 hour period. The tests will be repeated at least a week later and subjects receive a dose of dichloroacetate (DCA)

Full description

Subjects will be screened with a history and physical and have baseline laboratory values drawn to assure that the subject is healthy.Subjects will fast for 12 hours before the test. The next day they will receive a dose of 25mg of pyruvate dissolved in 80ml of Crystal Light. The pyruvate used in this study will be prepared with a nonradioactive form of carbon, called a stable isotope. It poses no hazard to the subject's health. About 50 mls of blood will be drawn over a 120 minute time period from an IV catheter placed in the arm. Subjects will also be asked to exhale into a plastic tube about 12 times in 120 minutes to collect 13C carbon dioxide (13CO2). Cells from inside of the mouth will be collected by subjects swishing a tablespoon of mouth wash for one minute and then spitting it into a sterile plastic tube. At least one week following the first admission subjects will return to repeat the above procedure and receive 25mg of dichloroacetate (DCA) one hour before receiving the pyruvate. Then the same samples will be collected. Subjects have the option of doing the tests 4 times receiving the DCA on the last visit.

Enrollment

5 patients

Sex

All

Ages

21 to 50 years old

Volunteers

Accepts Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria:- healthy volunteers

  • normal history,
  • normal physical
  • normal baseline laboratory data.

Exclusion Criteria:

  • Any illness
  • Chronic health condition
  • Use of street drugs
  • Taking medication
  • Abnormal labs Abnormal physical exam -

Trial design

Primary purpose

Health Services Research

Allocation

N/A

Interventional model

Single Group Assignment

Masking

None (Open label)

5 participants in 1 patient group

13C-pyruvate,13C-Lactate and dichloroacetate
Experimental group
Description:
During the first day of the subjects participation pyruvate will be given and blood, breath and buccal cell samples will be collected over a two hour period. On the last day DCA will be given.
Treatment:
Drug: 13C-Pyruvate 13C-lactate and dichloroacetate

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems